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Negligible Role of Antibodies and C5 in Pregnancy
Loss Associated Exclusively with C3-Dependent
Mechanisms through Complement Alternative Pathway
Membrane cofactor protein (MCP), decay accelerating
factor (DAF), and their mouse functional homolog, Crry,
are ubiquitous membrane-bound proteins that regulate
the activation of the third component of complement, C3
(Holers et al., 1992; Molina et al., 1992; Kim et al., 1995).
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Department of Medicine The need for these complement inhibitory proteins to
control complement-mediated tissue damage is evident2 Department of Pathology and Immunology and
3 Department of Obstetrics and Gynecology during pregnancy. The placenta expresses, throughout
gestation, high levels of complement regulators (HolmesWashington University School of Medicine
St. Louis, Missouri 63110 and Simpson, 1992). In addition, up to 20% of first tri-
mester pregnancy losses can be characterized by the
onset of hypocomplementemia and, in some conditions,
with complement deposition in the placenta (Cunning-Summary
ham and Tichenor, 1995). In some cases this hypocom-
plementemia is associated with reduced DAF expres-Factors involved in pregnancy failure due to abnormal
fetomaternal tolerance are poorly understood. Here sion on the placenta and increased complement
consumption at the fetomaternal interface. Complementwe describe distinct defects in placenta formation and
subsequent pregnancy loss solely dependent on the activation is also required in a mouse model of recurrent
fetal loss associated with anti-phospholipid antibodies,activation of the complement alternative pathway and
the effector mechanisms provided by the maternal C3. a condition characterized by increased miscarriages
and spontaneous abortion (Holers et al., 2002). Further-Surprisingly, this effect is independent of other com-
plement activation pathways and of the effector mech- more, deficiency in the mouse complement regulator
Crry leads to embryonic death (Xu et al., 2000). Crry/anisms provided by other complement components.
These findings provide significant insight into the role embryos suffer from increased C3 deposition and con-
comitant inflammation within the developing placenta.of the innate immune system in human pregnancy fail-
ure, a frequent clinical outcome. C3 involvement in the fetal death has been demon-
strated by the complete rescue of this abnormal pheno-
type in C3/ mice (Xu et al., 2000).Introduction
Several mechanisms may be involved in complement-
dependent pregnancy loss (Frank and Fries, 1991; Wet-The mammalian embryo has been compared to a tissue
transplant received from a genetically different individ- sel, 1995; Gerard and Gerard, 1994; Carroll, 1998; Rus
et al., 2001). Defining the relative contribution of theseual (Medawar, 1953). The reasons why the maternal im-
mune system does not view the paternal component mechanisms to fetal loss will facilitate the understanding
of the innate immune response during pregnancy andof the embryo as foreign and rejects it has perplexed
immunologists for more than fifty years. Fetal survival provide potential therapeutic options in the treatment
of recurrent miscarriages. To this purpose, we have usedduring pregnancy depends on the ability of embryonic
tissue to avoid rejection by the maternal immune system the Crry/ mouse model to further investigate the role
of complement and complement regulators in recurrent(Billington, 1992). The maintenance of this fetomaternal
tolerance is still poorly understood. Recent experimental fetal loss. Here, we identify the pathways related to the
activation of complement in the Crry/ embryos, theobservations suggest that inappropriate complement
activation during pregnancy impairs this type of immu- complement components needed to cause the fetal de-
mise, and the pathological consequences of this activa-noregulation (Rooney et al., 1993; Holmes and Simpson,
1992; Holers et al., 2002; Xu et al., 2000). tion. Surprisingly, activation of the maternal third com-
ponent of complement through the alternative pathway,The complement system consists of a series of serum
proteins involved in the regulation of the immune re- and the resulting neutrophil inflammation, is enough to
mediate defects in placenta formation and subsequentsponse and the inflammatory process by generating
fragments that promote chemotaxis, phagocytosis, cell pregnancy loss. This effect is independent of other com-
plement activation pathways and complement compo-activation, and cell lysis (Schmidt and Colten, 2000; Ab-
bas et al., 2000). This complex system provides one of nents, or the presence of B cells and antibodies. Thus,
abnormal fetomaternal tolerance may be establishedthe early defense mechanisms against pathogens. The
activation of complement, however, is not inconsequen- using exclusively C3 as both the inductive and effector
element without the contribution of downstream com-tial for the host. Activated complement fragments have
the capacity to bind to tissues, trigger inflammation, and plement components or mobilization of antibody-medi-
ated immune response components.cause injury. Autologous bystander cells are protected
from the deleterious effects of complement by express-
ing proteins that regulate its activation (Liszewski et al., Results
1996; Hourcade et al., 1989; Lublin and Atkinson, 1989).
Inconsequential Effect of the Classical Pathway
Complement activation occurs through three pathways*Correspondence: hmolina@imgate.wustl.edu
4These authors contributed equally to this work. (Volanakis, 1998). The classical pathway is initiated by
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Table 1. Genotype Analysis of 3-Week-Old Pups Derived from Crry/ Matings Using Mice with Deficiencies in Specific Complement
Components or Antibody-Deficient Mice
Crry/ Crry/ Crry/ Total
Expected 25% 50% 25%
Ratio [1] [2] [1]
Crry/ mating 150 (47%) [1] 168 (53%) [1.1]* 0 (0%) 318
C4/Crry/ mating 16 (29%) 39 (71%) 0 (0%) 55
MTCrry/ mating 22 (46%) 26 (54%) 0 (0%) 48
fB/Crry/ mating 12 (24%) 24 (49%) 13 (27%) 49
C5/Crry/ mating 22 (35%) 37 (60%) 3 (5%) 62
Numbers in brackets represent genotype ratios of embryos.
*p  0.0001 as calculated by the 2 goodness of fit test.
antigen-antibody complexes and the sequential activa- could be recovered from a total of 55 births, indicating
that the classical pathway is nonessential for the fetaltion of C1, C4, and C2. Fragments derived from the
rejection process affecting the Crry-deficient mice (Ta-activation of C4 and C2 form an enzyme known as the
ble 1). In agreement with this observation, 7.5 day post-classical pathway C3 convertase responsible for the acti-
coitus (dpc) C4/Crry/ embryos exhibited increasedvation of the third component of protein, C3. The lectin
C3 deposition similar to Crry/ embryos (Figures 1Bpathway is initiated by plasma proteins, known as man-
and 1C). Minimal C3 deposition was noted in Crry-suffi-nan binding lectins, which attach to carbohydrate moie-
cient embryos (Figure 1A). Associated with the increasedties on the surface of pathogens. Once bound, these
C3 deposition was also increased tissue inflammationlectins interact with mannan binding lectin-associated
in Crry/ and C4/Crry/ embryos as determined byserine esterases and induce the activation of C4, C3,
Gr-1 staining, a marker for neutrophils (Figures 2Band C2. The alternative pathway is initiated directly by
and 2C).the slow and spontaneous deposition of C3 on the target
surface, allowing binding and activation of factor B. In
the absence of complement regulation, the activated C3/ Effect of the Alternative Pathway
factor B bimolecular complex forms an enzyme directly The alternative pathway promotes complement activa-
responsible for further amplification of C3 activation and tion mainly on microbial surfaces and serves as an am-
the formation of enzymes involved in C5 activation. plification system for the classical and lectin pathway
Of the three pathways for complement activation, we (Jelezarova et al., 2000). It is unique in that no specific
considered the classical pathway as the most likely molecular recognition motifs on the target are required
pathogenic mechanism causing tissue damage to the for its activation. Due to the unexpected inconsequential
Crry/ embryos since this route to complement acitva- role of the classical pathway in the Crry/ phenotype,
tion is the primary effector mechanism in hyperacute we tested the hypothesis that the alternative pathway
and acute vascular rejection of transplanted tissue and provided the main mechanism of complement activation
for several hypersensitivity reactions (Geha et al., 2001). and fetal rejection. We bred the mice with the Crry muta-
tion to factor B-deficient mice (fB/) (Matsumoto et al.,Since the Crry mutation was initially present in a mixed
1997). Genotype analysis revealed that 27% (13/49) ofgenetic background, maternal allospecific antibodies
the resulting 3-week-old pups were fB/Crry/. Inreacting against fetal alloantigens could induce the acti-
agreement with this observation, 7.5 dpc fB/Crry/vation of this pathway. To test this possibility, we initially
embryos exhibited no increased C3 deposition (Figureexamined the effect of the Crry mutation in B cell-defi-
1D) and no neutrophil inflammation as determined bycient mice (MT) (Kitamura et al., 1991). TheMT mouse
Gr-1 staining (Figure 2D). These results indicate thatstrain was generated by creating a null mutation in the
complement components derived from the activation oftransmembrane exon of the immunoglobulin M (IgM)
the alternative pathway mediate the impaired fetomater-heavy chain resulting in the absence of serum antibod-
nal tolerance related with the Crry deficiency.ies. Compound MT/Crry/ mutant animals were
mated. Surprisingly, no MT/Crry/ pups were gen-
erated (Table 1). This observation ruled out an important Inconsequential Role of C5 Activation
contribution of the classical pathway in this phenotype The genetic analysis presented above excluded the role
and provided evidence for a dispensable role of antibod- of classical pathway components C1, C2, and C4 in the
ies and Fc receptors, not only as primary precipitating effector phase of tissue damage. Another mechanism
events, but also as effector mechanisms in the Crry/ of complement-mediated tissue damage involves the
embryonic lethality. activation of the fifth component of complement, C5
To further define the contribution of the classical path- (Abbas et al., 2000). Fragments derived from the activa-
way in the Crry/ phenotype, we examined the effect tion of C5 serve as potent chemoattractants and bind to
of the Crry mutation in mice deficient in C4 (Fischer et target surfaces, initiating the assembly of the membrane
al., 1996). We generated compound mutant mice that attack complex responsible for inducing abnormalities
were Crry/ and C4/, and subsequently crossed them in cell membrane. To determine the role of C5 in the
to generate mutants that were C4 deficient and either death of Crry-deficient embryos, we examined the effect
of the Crry mutation in a C5-deficient background. Sur-Crry sufficient or Crry deficient. No C4/Crry/ mice
Complement Regulation during Pregnancy
815
Figure 1. C3 Deposition in 7.5 dpc Fetal
Tissues
Tissue sections derived from decidua of wild-
type (A), Crry/ (B), C4/Crry/ (C), and
fB/Crry/ (D) embryos were stained with
an antibody against mouse C3. Extensive C3
deposition (arrows) is noted in the trophoec-
toderm area of Crry/ and C4/Crry/ fe-
tuses. The embryo proper is spared. d, mater-
nal decidua; e, embryo.
prisingly, lack of C5 failed to rescue the Crry/ embryos Effect of Maternal C3
Either the fetal or maternal environment could contributefrom embryonic death, indicating an expendable role
for C5 activation in the Crry/ embryonic lethality (Table C3 with the capacity to cause the embryonic death. To
investigate the role of fetal C3 in this phenotype, we1). Taken together, the above observations indicate that
the indispensable effector complement component in- initially examined expression of C3 in normal embryonic
tissues. Northern analysis demonstrated the absence ofvolved in the Crry/ embryonic lethality was C3 itself.
Figure 2. Neutrophil Tissue Infiltration in 7.5
dpc Fetal Tissues
Tissue sections derived from decidua of wild-
type (A), Crry/ (B), C4/Crry/ (C), and
fB/Crry/ (D) were stained with an anti-
body against Gr-1, a molecule that serves
as a marker for neutrophils. Gr-1 staining is
localized in the trophoectoderm area of
Crry/ and C4/Crry/ fetuses, but not
wild-type or fB/Crry/ deficient mice. d,
maternal decidua; e, embryo.
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Figure 3. C3 and C3 Regulator Expression in
Fetal Tissues
(A) C3 expression in 10.5 and 14.5 dpc pla-
centa and embryo proper as determined by
Northern blot analysis. RNA extracted from
liver was used as positive control. Actin is
used as a control for relative amounts of RNA.
(B and C) Northern blot analysis (B) and RT-
PCR analysis (C) for mouse MCP expression
in 10.5 dpc embryonic tissue.
(D) Staining of 10.5 dpc wild-type embryos
with anti-mouse DAF antibodies.
(E) Staining of 10.5 dpc Crry/ embryos with
anti-mouse DAF antibodies. d, maternal de-
cidua; e, embryo proper; p, placenta.
C3 expression by the placenta and the fetus on 10.5 cant fetal rejection. Mating C3/Crry/ males to
C3/Crry/ females, however, resulted in only 8% ofdpc embryos (Figure 3). Interestingly, at 14.5 dpc C3
mRNA was detected in the embryo but not in the pla- the pups (4 out of 51 pups) with a C3/Crry/ genotype
(p  0.001). Thus, these results indicate that maternalcenta, yet the relative amount of C3 mRNA was lower
than in liver of wild-type adult mice. Importantly, this C3 is responsible for the Crry/ embryonic death.
Histological analysis revealed that maximal C3 depo-gestational age in our model is beyond the time of fetal
rejection (Xu et al., 2000). Thus, the relative absence of sition and inflammation occurred at 7.5 dpc (Xu et al.,
2000). Increased C3 deposition and inflammation wasdetectable fetal C3 mRNA at the time of fetal demise
suggested that fetal C3 was not involved in the also noted at 8.5 dpc (data not shown). Surprisingly, at
9.5 and 10.5 dpc similar C3 deposition was noted in wild-Crry/ phenotype.
To examine whether maternal C3 was primarily re- type and Crry-deficient extraembryonic tissues (Figures
4A and 4B), and inflammation was absent in Crry-defi-sponsible for the Crry/ phenotype, we initiated studies
in which the main experimental variable was the pres- cient embryos at these gestational ages (Figures 4F–4H,
5B, and 5D).ence or absence of maternal C3. We bred C3/Crry/
mice to C3/Crry/ mice. According to Mendelian ge- As noted above, the maximal deposition of C3 at 7.5
dpc in Crry/ mice preceded by 3 days the embryonicnetics, the expected genotypes of pups derived from
this mating combination should be C3/Crry/ (50%) loss evident at 10.5 dpc, suggesting that C3 activation
did not immediately cause fetal death. This delay in theand C3/Crry/ (50%) (Table 2). Mating C3/Crry/
males to C3/Crry/ females did not result in signifi- embryonic loss could be explained by the expression of
Table 2. Role of Maternal C3 in the Lethality Found in Crry/ Embryos
C3/Crry/ C3/Crry/ Total
C3/Crry/  C3/Crry/ (expected) 50% 50%
C3/Crry/ (male)  C3/Crry/ (female) 30 (60%) 20 (40%) 50
*C3/Crry/ (male)  C3/Crry/ (female) 47 (92%) 4 (8%) 51
* p  0.0001.
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Figure 4. Abnormal Placenta Development Induced by C3 Deposition in Crry/ Fetal Tissue
(A) C3 deposition in 9.5 dpc Crry/ mice. 45, magnification.
(B) C3 deposition in 9.5 dpc Crry/ mice. 45, magnification.
(C and D) Anti-cytokeratin staining of (C) Crry/ and (D) Crry/ embryos. 25, magnification.
(E) Hematoxylin and eosin staining of 9.5 dpc Crry/ placenta. 100, magnification. Note the discrete area of labyrinthine trophoblast cells
in the placenta (lt), adjacent to the allantoic mesenchyme, that contains developing fetal blood vessels (av).
(F) Hematoxylin and eosin staining of 9.5 dpc Crry/ placenta. 100, magnification.
(G and H) Hematoxylin and eosin staining of 9.5 dpc Crry/ placenta. 200, magnification. a, allantoic mesenchyme; av, allantoic vessels;
cma, central maternal artery; d, maternal decidua; e, embryo proper; lt, labyrinthine trophoblast cells; pys, parietal yolk sac; tgc, trophoblast
giant cells; vys, visceral yolk sac.
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additional complement regulatory molecules by mouse (Figures 4F and 4G) or 10.5 dpc (Figure 5). The spongio-
trophoblast area, the central artery of the maternal de-trophoblats. In previous work we described the absence
of DAF expression in murine 7.5 dpc wild-type tropho- cidua, and the trophoblastic giant cells at the periphery
of the labyrinthine plate (Figure 4H) were present withoutblasts (Xu et al., 2000). However, it is known that tropho-
blast DAF expression increases with advancing human differences between Crry/ and Crry/ placentas.
There were additionally no observable differences in thegestation (Hsi et al., 1991; Holmes et al., 1992). Upregula-
tion of this protein in response to complement attack histology of the amnion, the visceral yolk sac placenta,
or the parietal yolk sac between Crry/ and Crry/has also been observed in vitro (Shibata et al., 1991). In
addition, MCP and DAF are present in human tropho- mice (Figures 4F and 4H). Thus, histological findings at
9.5 and 10.5 dpc demonstrated a failure in the develop-blasts (Hsi et al., 1991; Holmes et al., 1992). Expression
of MCP or DAF with advancing gestation, possibly in- ment of the allantoic vasculature in the component of
the placenta.duced by complement deposition, is a plausible regula-
tor in our model. To rule out this possibility, we examined
for the presence of mouse MCP and DAF in the placenta. Discussion
By Northern blot and RT-PCR analysis, we did not detect
expression of MCP mRNA in 10.5 dpc wild-type embryos Recurrent pregnancy loss affects 1% to 3% of all cou-
and placentas (Figures 3B and 3C). As expected, MCP ples, and about half of these cases have no identifiable
mRNA was detected in mouse testis (Tsujimura et al., cause (Hill, 1992). Importantly, recent studies associate
1998). In addition, although maternally derived decidua some of these pregnancy complications with an abnor-
does express DAF, there is no DAF expression in 10.5 mal maternal immune response (Billington, 1992; Vince
dpc placenta and embryos of wild-type or Crry/ fe- and Johnson, 1995; McIntyre, 1992). The fetus ex-
tuses as determined by immunohistochemistry (Figures presses many paternally derived cell surface molecules
3D and 3E). Thus, the time difference between maximal foreign to the immune system of the mother. Fetal sur-
complement activation at 7.5 dpc and embryonic loss vival during pregnancy greatly depends on the ability
at 10.5 dpc is not related to the presence of additional of fetal tissue to avoid recognition and rejection by the
membrane-bound complement regulators in either the maternal immune system. Thus, abnormalities in the regu-
fetus or placenta. lation of the maternal immune response against the fetus
are potentially an identifiable cause for pregnancy failure
(Billington, 1992).
Defects in Placental Development Accumulating data suggest a role for the complement
In agreement with the selective deposition of comple- system as a causative and perpetuating element in re-
ment and the inflammation noted on 7.5 dpc ectoplacen- current fetal loss (Rooney et al., 1993; Holmes and Simp-
tal tissue, the main pathological changes were seen in son, 1992; Holers et al., 2002; Xu et al., 2000). Neverthe-
the Crry/ placentas. The visceral yolk sac placenta is less, these studies have not identified the relative
the key source for fetal nutrients in the mouse until contribution of the activation and effector mechanisms
day 9.5 when a transition to the labyrinthine placenta that may be involved in this complement-dependent
provides the primary location for maternal-fetal ex- pregnancy loss. Formation of pathogenic antibodies
change (Vince and Johnson, 1995). We therefore fo- with activation of the classical pathway may have a role
cused on the histology of the mouse labyrinth during (Geha et al., 2001), but this mechanism fails to character-
this gestational period, comparing Crry/ with Crry/ ize the majority of cases with unexplained multiple spon-
mice. The presence of trophoblast in both Crry/ and taneous miscarriages (Hill, 1992; Vince and Johnson,
Crry/ placentas was confirmed by the characteristic 1995). Other possibilities include increased complement
cell morphology (Kaufman, 1998) and the positive cyto- activation through lectin-mediated recognition of pla-
keratin staining (Figures 4C and 4D), a marker for this cental carbohydrates or hydrolytic activation of C3 dur-
cell population (Adamson et al., 2002). The labyrinthine ing tickover of the alternative pathway (Pangburn and
of Crry/ mice at 9.5 dpc had a discrete area of tropho- Muller-Eberhard, 1980). Despite these theoretical mech-
blasts adjacent to the allantoic mesenchyme that con- anisms, the initial trigger for increased activation of the
tained developing fetal blood vessels (Figure 4E). Fetal alternative or lectin pathways in complicated pregnan-
vessels originating from the Crry/ allantoic mesen- cies, compared to normal pregnancies, remains elusive.
chyme penetrated the connective tissue of the labyrin- The Crry/mouse is an excellent model for examining
thine columns that were themselves covered with the the role of complement in pregnancy failure. This model
trilayer of trophoblast bathed in maternal blood derived has elucidated a key role of fetal complement regulation
from the decidual central artery. Thus, dual perfusion of in the control of maternal-mediated tissue damage. The
the labyrinthine placenta in the Crry/ mice was clearly analysis presented in this paper indicates that primary
apparent by 9.5 dpc. genetic abnormalities in the placental expression of
The placental development at 9.5 dpc in the Crry/ complement regulators act as an initial triggering factor
mice was strikingly different from wild-type mice. There in fetal loss by causing increased complement activation
was a marked deficiency of vessels in the Crry/ allan- through the alternative pathway. Surprisingly, experi-
toic mesenchyme at 9.5 dpc, yet an aggregate of labyrin- mental observations derived from the use of B cell-
thine trophoblast cells was present at this stage (Figures deficient and C4-deficient mice indicate that pathogenic
4F and 4G). Importantly, there were no detectable allan- antibodies activating the classical pathway are not pre-
toic vessels penetrating the labyrinthine trophoblast to cipitating stimuli. In the case of the lectin pathway, in
vitro analyses have demonstrated that activation of C3yield the usual fetal vascular spaces at either 9.5 dpc
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Figure 5. Abnormal Vascular Development of
the Placenta Induced by C3 in Crry/ Fetal
Tissue
Crry/ (left panel) and Crry/ (right panel)
embryos.
(A and B) Decidua dissection to expose the
10.5 dpc placenta. 100, magnification.
(C and D) 10.5 dpc placenta. 200, magnifi-
cation. Note the lack of detectable allantoic
vessels penetrating the labyrinthine tropho-
blast to yield the usual fetal vascular spaces.
a, allantois; d, maternal decidua; bv, blood
vessel; e, embryo proper; l, vascular labyrin-
thine placenta.
through this pathway may occur in the absence of C4 complement activation even in normal pregnancies (Hol-
ers et al., 2002) (Figure 4A). This complement deposition(Matsushita et al., 2000). There is no conclusive evi-
dence, however, that mammalian mannose binding pro- is devoid of an inflammatory reaction and apparently
does not affect the pregnancy. The reason why C3 depo-teins have the ability to recognize self-glycoproteins and
spontaneously initiate this pathway in vivo in the ab- sition is present in the wild-type fetus is not known. In
addition, it is not known whether the comparablesence of pathogens (Hoffmann et al., 1999). Conse-
quently, in this experimental model of abnormal fetoma- amount of noninflammatory C3 activation noted in the
9.5 dpc Crry/ embryos is still harmful to the fetus, orternal tolerance, the alternative pathway of complement
activation is a primary contributor to fetal loss and not why, in the absence of membrane-bound C3 regulators,
the degree of complement deposition is not increasedjust an amplification system surrogated to the classical
and lectin pathways (Jelezarova et al., 2000). Comple- as compared to wild-type mice (Figure 4B).
The inflammatory reaction in this model of fetal lossment components derived from the activation of the
maternal alternative pathway provide sole factors that is composed mainly of neutrophils. Staining with anti-
bodies against mouse Ig, B220, CD3, Thy-1, CD11b, F4/cause tissue destruction.
The above outcome provides insight into the comple- 80 has yielded negative results suggesting a paucity
of B cells, T cells, and macrophages in this type ofment components needed to effect the fetal demise. On
the basis of the above observations we conclude that inflammation (data not shown). In addition, no mast cells
have been detected as assessed by staining with 0.1%the indispensable effector complement component in-
volved in the Crry/ embryonic lethality is C3 itself. methylene blue staining.
We postulate that the C3 inflammation identified atThe experimental observations derived from the genetic
analysis exclude the role of classical pathway compo- 7.5 dpc ultimately leads to fetal demise by injuring com-
ponents destined to become the allantoic vessels of thenents C1, C2, and C4 in the effector phase of tissue
damage. Although complement-mediated tissue dam- labyrinthine chorioallantoic placenta (Sherer and Abu-
lafia, 2001; Reynolds and Redmer, 2001). The inade-age can drive from the activation of the fifth component
of complement, C5, lack of C5 did not rescue the Crry/ quate development of the allantoic vessels, apparent
by 9.5 dpc in the Crry/ mice, yields an insufficientembryos from embryonic death (Table 1) (Gerard and
Gerard, 1994; Nicholson-Weller and Halperin, 1993). This vascular supply between the fetus and the labyrinthine
placenta. This is the time when the fetus normally transi-suggests an expendable role for the potent soluble in-
flammatory anaphylatoxic and chemotactic molecule tions from dependence for nutrition on the visceral yolk
sac placenta at 9.5 dpc to the labyrinthine placentaC5a and the C5b-9 membrane attack complex.
A unique finding is the exclusive role and effectiveness at 9.5 dpc The dual hemochorial blood supply to the
labyrinthine placenta, which is required for ongoing ma-of fragments derived from C3 activation in the induction
of the observed pregnancy failure. C3a is a potent solu- ternal-fetal exchange, is thus not available to support
nutritional development of the fetus beyond the ob-ble inflammatory anaphylatoxic molecule that increases
vascular permeability and promotes the recruitment of served embryonic lethal gestation of 10.5 dpc, as the
visceral yolk sac placenta becomes an inadequate nutri-inflammatory cells. C3a also mediates endothelial cell
activation and induction of adhesion molecules through tional source. This finding suggests that the complement
system plays a key role in vascular development of theits receptor (C3aR, CD88). C3b and iC3b enhance
phagocytosis through interaction with complement re- labyrinthine placenta. We do not know whether comple-
ment dysfunction might contribute to early pregnancyceptor 1 and 3 on the surface of inflammatory cells.
A small amount of C3 staining was detected in 9.5 losses through a similar mechanism in human gesta-
tions. Surprisingly, at the 10.5 dpc time of embryonicand 10.5 dpc wild-type extraembryonic tissue confirm-
ing previous observations concerning the presence of loss, comparable C3 deposition is noted in the fetuses
Immunity
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of Crry/ and wild-type mice, and no inflammation is future experiments using specific murine complement
inhibitory reagents as they become available.present. Thus, unlike the allantoic vasculature, the ves-
sels in the fetus do not show effects from the comple- Although a complete Crry deficiency gives the most
dramatic phenotype, our results demonstrate that evenment deposition.
Our data also imply the existence of potential thera- a partial decrease in the expression and/or function of
these regulators is sufficient to increase the rate of fetalpeutic targeting areas based on complement regulation.
At least in our model, complement regulation at the level loss (Table 1). Analysis of the Crry/ mating revealed
a deviation from the expected Mendelian ratio betweenof C5, or distal to C5, is not effective in controlling this
phenotype. Targeting C3 directly may not be desirable the Crry/ and the Crry/ of 1:2 to 1:1, indicating that
45% of Crry/ embryos were also lost (Table 1). Thesedue to the important contribution of this molecule to the
priming of adaptive immune responses and its role in results may also apply to human pregnancy loss in which
a decrease, and not necessarily a complete deficiency,immune complex handling (Abbas et al., 2000). Alterna-
tively, specific regulation of the alternative pathway may in complement regulators within the placenta could in-
crease the rate of fetal miscarriages. Therefore, ourprovide a practical, less noxious way of controlling tis-
sue inflammation. studies indicate that further evaluation of this patho-
genic mechanism of fetomaternal intolerance is nowAnother interesting feature in our model of fetal loss
is the inconsequential contribution of humoral immune warranted in human pregnancy loss.
responses to the development of this phenotype. Anti-
Experimental Proceduresbody-mediated mechanisms of tissue damage, includ-
ing the role of immunoglobulin Fc receptors, have a
Mice
negligible role. We have not ruled out directly a role for F1(129Sv/J x C57BL/6) Crry/ mice were generated using standard
cellular immune responses. It is noteworthy to point out, gene targeting techniques as previously described (Xu et al., 2000).
C57BL/6 C4-deficient mice were obtained from Dr. Michael Carrollhowever, that we have bred Crry heterozygous mice six
of Harvard University (Fischer et al., 1996). (129Sv/J x C57BL/6)generations into the C57BL/6 background. Mating of
B cell-deficient mice (MT/) were originally obtained from Thethe resultant Crry/ mice has yielded no Crry/ mice
Jackson Laboratory (Bar Harbor, ME) (Kitamura et al., 1991).out of 54 pups analyzed, except in a concurrent C3-
F1(129Sv/J x C57BL/6) factor B and C3-deficient animals were ob-
deficient background. Thus, the occurrence of Crry/ tained from Dr. Harvey Colten (Matsumoto et al., 1997; Circolo et
fetal loss in syngeneic mice suggests that cellular im- al., 1999). Detection of the mutant alleles was performed by PCR
analysis of tail DNA as previously described. B10.D2-H2d mice defi-mune responses may have a limited effect. Experiments
cient in C5 were obtained from The Jackson Laboratory. They wereusing T cell-deficient mouse models are underway to
maintained under specific pathogen-free conditions.substantiate the above observation.
Mice used in these experiments are in a F1(129svJ x
Immunohistochemistry
C57BL/6) mixed genetic background except the C5/ Deciduas were removed and frozen quickly in OCT compound
and C4/ and the mice that are in a B10.D2-H2d and (Miles, Elkhart, IN), and 10 m thick sections were cut. Endogenous
peroxidase was quenched with 0.2% H2O2 in methanol. SectionsC57BL/6 background, respectively. It can be argued that
were first incubated with goat anti-mouse C3 (Cappel, Aurora, OH)this genetic heterogeneity complicates data interpreta-
followed by rabbit anti-goat IgG conjugated to HRP (Southern Bio-tion since one can attribute the mitigating effects of
technology), rat anti-mouse Gr-1 (Ly-6G) (Pharmigen, San Diego,particular complement deficiencies on genetic back-
CA) followed by rabbit anti-rat IgG conjugated to HRP (Southern
ground differences that are independent of complement Biotechnology). Some sections were stained for cytokeratin, a
itself. As pointed out above, however, the absolute em- marker for trophoblast cells (Adamson et al., 2002), using a rabbit
anti-cytokeratin antibody (DAKO Corporation, Carpinteria, CA) fol-bryonic lethality related to F1(129svJ x C57BL/6) Crry
lowed by goat anti-rabbit IgG conjugated to HRP (Southern Biotech-mice persists in a C57BL/6 mouse strain, suggesting
nology). In some experiments 10.5 dpc deciduas were stained withthat genetic differences provided by the mouse strains
goat anti-rat/mouse DAF (Research Diagnostics, Inc., Flanders, NJ)used in these experiments are not a major reason for
followed by rabbit anti-goat IgG conjugated to HRP (Southern Bio-
the Crry/ fetal loss. Moreover, this embryonic lethality technology). Bound HRP was detected with diaminobenzidine. Sec-
can be rescued in C57BL/6 C3-deficient mice, but not tions were counterstained with 1% methylgreen and covered with
crystal-mount (Biomeda, Foster City, CA). Some deciduas were fixedin C57BL/6 C4-deficient mice, validating the inconse-
with 10% buffered formalin, embedded in paraffin, sectioned, andquential role of the classical pathway in this phenotype.
stained with hematoxylin and eosin for pathological analysis.In addition, the experiments analyzing the role of C3,
factor B, and B cells in the Crry-related fetal loss are
Northern Blot
performed in a F1(129svJ x C57BL/6) genetic environ- Total RNA was isolated by homogenizing tissue samples in TRIzol
ment. The F1(129svJ x C57BL/6) mouse strain does not reagent (Gibco BRL, Rockville, MA) using a power homogenizer
according to the manufacturer’s instructions. Electrophoresis wasprovide a genetic background in which recurrent in-
performed in 0.9% agarose and 0.6% formaldehyde in a buffer con-creased spontaneous abortions occur, facilitating the
taining 0.02 M morpholinopropanesulfonic acid, 5 mM sodium ace-comparison between F1(129svJ x C57BL/6) mice with
tate, and 1 mM EDTA. RNA was transferred to a nylon membrane
different targeted genes, including Crry/ mice, and probed with a C3 cDNA fragment or an MCP cDNA fragment
fB/Crry/ mice, C3/Crry/ mice, and MT/Crry/ (Tsujimura et al., 2001; Circolo et al., 1999). Hybridization and wash-
ing were performed using the same conditions as above exceptmice, since the mouse strain is not a variable. Further-
that 50% formamide was added to the hybridization buffer andmore, a genetic heterogeneous background increases
performed at 42C and washing at 56C.the significance of our studies as applied to genetically
heterogeneous human populations. Further supporting RT-PCR Analysis
evidence of the role of different complement compo- Total RNA was isolated from testis or placenta and subjected to
RT-PCR using the Access RT-PCR system (Promega, Madison, WI).nents in the Crry-induced phenotype will come from
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The following oligonucleotides were used for MCP: 5	-CACGGC Hoffmann, J.A., Kafatos, F.T., Janeway, C.A., Jr., and Ezekowitz,
R.A.B. (1999). Phylogenetic perspectives in innate immunity. Sci-CATTTGAAGCTATGGAACTCAAGGG-3	 and 5	-AATATCATGCTTG
TTCCAACA-3	 (Tsujimura et al., 2001). Mouse 
-actin was used ence 284, 1313–1318.
as positive control. Oligonucleotides for mouse 
-actin were Holers, V.M., Kinoshita, T., and Molina, H. (1992). The evolution of
5	-TGTGATGGTGGGAATGGGTCAG-3	 and 5	-TTTGATGTCACG mouse and human complement C3-binding proteins: divergence of
CACGATTTCC-3	 (Stratagene, La Jolla, CA). PCR amplification was form but conservation of function. Immunol. Today 13, 231–236.
performed at 94C for 2 min, followed by 23 cycles of 94C for 0.5
Holers, V.M., Girardi, G., Mo, L., Guthridge, J.M., Molina, H., Pier-
min, 55C for 1 min, 68C for 1 min, and ending with 72C for 10
angeli, S.S., Espinola, R., Xiaowei, L.E., Mao, D., Vialpando, C.G.,
min. The PCR products were analyzed in a 1.5% agarose gel. The
and Salmon, J. (2002). Complement C3 activation is required for the
predicted size of the RT-PCR products for both the 
-actin and
antiphospholipid antibody-induced fetal loss. J. Exp. Med. 195,
MCP reactions is around 500 base pairs.
211–220.
Holmes, C.H., and Simpson, K.L. (1992). Complement and preg-Statistical Analysis
nancy: new insights into the immunobiology of the fetomaternalLevels of statistical significance were determined using the 2 good-
relationship. Baillieres Clin. Obstet. Gynaecol. 6, 439–460.ness of fit test.
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